Navigation Links
NHLBI funds preclinical tests on devices for infants and children with congenital heart defects

The National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health, has awarded four contracts totaling $23.6 million to begin preclinical testing of devices to help children born with congenital heart defects or those who develop heart failure. The four-year program is called Pumps for Kids, Infants, and Neonates (PumpKIN).

Each year in the United States, nearly 1,800 infants die as a result of congenital heart defects and another 350 develop heart disease, which leads to heart failure for many. Approximately 60 infants and children under 5 years old who are placed on the heart transplant waiting list die each year before receiving one. Mechanically assisted circulatory support could be used to sustain these young patients as they seek to recover or wait to receive a heart transplant.

"This research seeks to develop technologies to expand life-saving options for infants and children born with congenital heart defects or those who develop heart failure," said NHLBI Acting Director Susan B. Shurin, M.D., a pediatrician. "The NHLBI is committed to saving the lives of our youngest patients. Well-designed circulatory support devices are expected to substantially improve the outcomes of the infants and young children who need them as they seek to recover or wait to receive a heart transplant."

The options for chronic circulatory support devices for infants and young children are limited, and all have substantial risks for serious adverse events such as infection, stroke, and device failure. With this in mind, the NHLBI launched the Pediatric Circulatory Support Program in 2004 by funding the development of five novel circulatory support devices for infants and young children with congenital and acquired cardiovascular disease.

The PumpKIN program is the next phase of NHLBI support for the development and clinical realization of these devices. The program's goal is to complete the needed animal studies and other tests in artificial environments for the most promising devices in order to gain approval from the FDA to begin clinical testing.

Devices in the program will provide suitable circulatory support for newborns, older infants, and children less than 55 pounds who experience heart failure due to congenital and acquired cardiovascular disease. They are designed to supply adequate blood flow to prevent organ damage while minimizing the risk of blood vessel damage, infection, breakdown of red blood cells, excessive bleeding, brain damage, and dangerous blood clots. The devices are intended to support circulation in pediatric patients for one to six months, be sufficiently small and reasonably portable, and be able to be routinely positioned and functioning in less than one hour, among other specifications.

"Similar devices are used in adults," Shurin noted. "As an adult, your heart is normally about the size of your fist; devices for small children require radically different designs from adult devices to adapt to the differences in the size of the patients."

The program will test ventricular assist devices (VADs) and advanced extracorporeal membrane oxygenator (ECMO) devices. The VADs in the PumpKIN program are very small rotary pumps which are implanted to provide circulatory support for extended periods of use. They work by drawing blood from the heart and pumping it to the body. ECMO devices circulate and supply oxygen to the blood, and are commonly used for patients who need both heart and lung support. For ECMO devices, tubes connecting the patient to the device are placed directly into large blood vessels near the base of the neck. Blood is drawn from the right side of the heart, pumped through the oxygenator, and then returned to the body on the left side of the heart so the oxygen-rich blood can be delivered throughout the body.

The contractors will conduct all preclinical animal testing and analysis in the first three years of the contract. During the third year, they will partner with a data coordinating center (the contract for which is still to be awarded) to complete the necessary activities to seek FDA approval to begin the clinical trial.


Contact: NHLBI Communications Office
NIH/National Heart, Lung and Blood Institute

Related medicine news :

1. ASH Honors Speaker of the House Nancy Pelosi and NHLBI Deputy Director Susan Shurin, MD, for Their Public Service, Leadership, and Commitment to Biomedical Research
2. Porter Novelli Begins Work With NHLBI on COPD Awareness Effort
3. NHLBI stops study of pulmonary hypertension treatment in sickle cell patients
4. Highlights of NHLBI-supported research presented at American Heart Associations Scientific Sessions
5. Pitt part of $100 million NHLBI Bench to Bassinet effort in congenital heart disease
6. NHLBI publishes new heart healthy cookbook
7. BlueCare(R) Family Plan, a HUSKY Health Plan from Anthem Blue Cross and Blue Shield in Connecticut, Raises Awareness, Funds and Diapers for New Haven Diaper Bank
8. Canadas government funds $1.6M in modern geography to support public health decisions
9. Computerized Jump Rope Raises Funds for Breast Cancer Research
10. Bally Total Fitness Emerges From Chapter 11 and Closes Transaction with Harbinger Capital Partners Funds
11. New Study Finds Medicaid Under-Funds Long Term Care by $4.4 Billion Annually
Post Your Comments:
(Date:10/13/2015)... (PRWEB) , ... October 13, 2015 , ... With Fall ... heat styling tool for this month’s Facebook Hair Styler Contest. , Enter to win! ... Contest Image Answering: What Is Your Favorite Hair Style? , 3. Follow us on ...
(Date:10/13/2015)... , ... October 13, 2015 , ... ... for children with autism, PediaPlex , a Southlake, Texas, child development and ... ABA Therapy and educating military families about their options for receiving this ...
(Date:10/13/2015)... ... 2015 , ... Bambeco, Inc., the premier brand for designing, ... closed on a $20.5 million funding round led by ABS Capital Partners, a ... continued rapid growth and expansion, broaden the Company’s product offerings, and expand its ...
(Date:10/13/2015)... ... October 13, 2015 , ... ... Vereb has been named the organization’s Executive Vice President of Operations, and three ... to key leadership roles in the company. , Debbie Vereb’s appointment to Executive ...
(Date:10/13/2015)... ... October 13, 2015 , ... Curly Hair Solutions® is thrilled ... Toronto, an exhibition featuring the newest products and services to hit the market ... be more excited to unveil their recent partnership with Trade Secrets, a leading ...
Breaking Medicine News(10 mins):
(Date:10/12/2015)... 2015 Given the intricacy of the ... to deliver an ophthalmic drug effectively to a specific ocular ... ocular drug delivery. These include dilution of a drug by ... conjunctiva and drug permeation issues with respect to the cornea, ... eye drops, is lost due to the aforementioned barriers. ...
(Date:10/12/2015)... N.J. , Oct. 12, 2015  Shareholder rights ... a securities fraud class action complaint was filed in ... Jersey.  The complaint alleges that officers and directors of ... Act of 1934 between September 15, 2015 and October ... about Amicus Therapeutics, business prospects.  Amicus is a biopharmaceutical ...
(Date:10/12/2015)... 12, 2015  Millions of smokers worldwide have used ... of tobacco. An April 2015 study released ... showed electronic cigarettes to be up to 95 percent ... a decade after the technology was first introduced the ... --> --> Palm ...
Breaking Medicine Technology: